AstraZeneca (AZN) announced positive results from the ongoing phase III EMERALD-I study, which is evaluating Imfinzi (durvalumab) as a combination therapy in hepatocellular carcinoma (HCC), the most common form of liver cancer.The EMERALD-1 study is evaluating the combination of Imfinzi combined with bevacizumab and transarterial chemoembolization (TACE), compared with TACE alone, for the treatment of unresectable HCC in patients eligible for embolization.The study achieved its primary endpoint of statistic ...

Zacks Style Scores - Zacks Premium提供了多种方式帮助投资者更加智慧和自信地投资[1] - Zacks Style Scores是一组辅助指标，帮助投资者挑选未来30天内市场表现最佳的股票[4] - Style Scores分为价值评分、成长评分、动量评分和VGM评分四个类别，分别评估股票的不同特征[6][7][8][9]

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca announces AIRSUPRA® (albuterol/budesonide), is now commercially available in the US by prescription. AIRSUPRA received FDA approval in January 2023 for the as-needed treatment or prevention of symptoms of asthma and to help prevent sudden severe breathing problems (asthma attacks) in people aged 18 years and older.1 AIRSUPRA contains a short-acting beta2-agonist (SABA), to help relax the smooth muscles of the airways, and an inhaled corticosteroid (ICS), to he ...

Astrazeneca股价表现 - Astrazeneca (AZN) 最新收盘价为 $66.54，较前一天上涨了 +0.03% [1] - Astrazeneca 过去一个月的股价涨幅为 0.33%，落后于医药行业的涨幅 3.16% 和标普500指数的涨幅 0.94% [2] Astrazeneca财报预测 - Astrazeneca 预计在即将公布的财报中，每股收益将达到 $0.79，较去年同期增长 14.49%，季度营收预计为 121 亿美元，较去年同期增长 8% [3] Astrazeneca业绩分析 - 分析师和投资者将密切关注 Astrazeneca 的业绩表现，近期的分析师预测变动通常代表着近期业务趋势的变化，正面的预测修正可视为公司业务前景的良好迹象 [4]

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores.What are the Zacks Style Scores?Developed alongside ...

公司背景 - 阿斯利康是一家全球科学引领的生物制药公司，专注于发现、开发和商业化处方药物，包括肿瘤学、罕见疾病和生物制药，包括心血管、肾脏与代谢以及呼吸与免疫学领域[58] IMFINZI® (durvalumab)治疗 - IMFINZI是一种人源单克隆抗体，与PD-L1蛋白结合并阻止PD-L1与PD-1和CD80蛋白的相互作用，对抗肿瘤的免疫逃逸策略，释放免疫反应的抑制[37] - IMFINZI已在美国、欧盟、日本、中国和许多其他国家获批用于与IMJUDO（tremelimumab-actl）联合治疗不可切除的肝细胞癌，在TOPAZ-1和HIMALAYA Phase III试验中取得积极结果[38] IMFINZI治疗效果 - IMFINZI与TACE和贝伐珠单药治疗相比，在肝细胞癌（HCC）患者中显示出显著的临床意义的进展无病生存（PFS）改善[1] - 在EMERALD-1试验中，IMFINZI加TACE和贝伐珠治疗组的疾病进展或死亡风险降低了23%[4] 安全性评估 - IMFINZI加TACE和贝伐珠治疗组的安全性良好，与每种药物的已知安全性一致，没有观察到新的安全信号[11]

UBS has revised its stance on two major UK-listed pharma companies - GSK PLC (LSE:GSK, NYSE:GSK) and AstraZeneca PLC (LSE:AZN) - with an upgrade for the former and a downgrade for the latter. GSK is moved from 'sell' to 'buy,' while the investment bank's call on AZ moves in the opposite direction. Positivity over stock in GSK is underpinned by optimistic projections for Shingrix, its shingles vaccine. UBS anticipates Shingrix sales will outperform consensus expectations, driven by a new market opportunity i ...

Over 300 companies, including AstraZeneca, Anglo American, Endeavour Mining, Heathrow Airport and British American Tobacco, will start to include nature-related disclosures as part of their annual corporate reporting. Some of the early-adopter companies, which have a combined value of US$4 trillion, have committed to begin reporting on nature-related issues in their 2023 results, while others will start with their 2024 or 2025 results, it was announced as the agreement was formalised at the Davos summit tod ...

UBS analysts shook up their ratings of European drugmakers, including making a double-downgrade of AstraZeneca and a double-upgrade of U.K. rival GSK.UBS took its ratings on AstraZeneca AZN, -2.82% AZN, +0.35% to sell from buy, while it upgraded GSK GSK, -0.44% GSK, +1.16% to buy from sell. It also upped Novartis NOVN, +0.25% NVS, -0.14% and Sanofi SAN, +0.03% SNY, -0.51% to buy from neutral, and Novo Nordisk NOVO.B, -0.19% NVS, -0.14% to neutral from sell.Analysts led by Matthew Weston say sector valuation ...

公司前景 - 摩根大通维持对阿斯利康公司的看涨态度，给出了每股130英镑的目标股价[1] - 阿斯利康公司首席财务官Aradhana Sarin关注了该药企的产品线潜力，并计划在本年代末推出15种新疗法[2] - 公司重申了将在2024年保持研发支出与营收比例的承诺，即使在产品线有强劲有机增长和最近的收购的情况下[3] - 阿斯利康公司预计将支持另一年的两位数每股收益增长，可能缓解市场对增长显著放缓的担忧[4] 公司发展计划 - 阿斯利康公司计划在2025年前实现低两位数复合年增长率的中期营收增长指引[5] - 公司还专注于将营运利润率扩大到中期的30%左右[7] - 阿斯利康公司预计2024年及以后，研发支出将保持在低20%的范围内[7] 产品研发和收购 - 阿斯利康公司预计2024年第一季度FDA将接受Dato-DXd TL01在2L+肺癌的申请[8] - 阿斯利康公司最近收购的Icosavax公司，特别是其病毒样颗粒（VLP）平台和RSV/hMPV疫苗，增强了公司的疫苗产品[9] - 公司认为在自身免疫性疾病中应用细胞疗法具有巨大潜力[10] 产品前景 - 对Tagrisso在III期不可切除肺癌的LAURA研究的成功信心依然很高，预计本季度有结果[11] - 预计Enhertu在DB06和DB09的即将公布的结果将进一步增加增长潜力[12] 股价信息 - 公司股价在早盘交易中持平，报108.08英镑[13]